VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon May 08, 2024 6:40pm

85 Views

Post# 36029927

🚀 Exciting Development from Ventripoint Diagnostics Ltd. 🚀

Exciting Development from Ventripoint Diagnostics Ltd.

We are thrilled to share that our advanced AI-powered heart-scanning software, VMS+4.0, has been submitted to the U.S. Food and Drug Administration (FDA) for clearance as of May 1, 2024. This innovation is poised to revolutionize cardiac diagnostics with precision and ease.

Spotlight Features of VMS+4.0:

VMS Strain and Heat Maps: Our latest software introduces enhanced visualization tools, including strain and heat maps that accurately depict the detailed mechanics of heart muscle movements. These tools offer cardiologists deeper insights into cardiac function, enabling better patient management.

Automated Plotting of Key Anatomical Landmarks: With VMS+4.0, the manual plotting of cardiac landmarks is a thing of the past. Our technology automatically identifies and maps critical points within the heart, significantly boosting the confidence, reliability, consistency, and reproducibility of volumetric measurements. This automation not only saves time but also enhances the precision of cardiac assessments.

These features ensure that VMS+4.0 can deliver MRI-quality images and analyses quickly and reliably, making advanced cardiac care accessible in minutes.

Global Outreach:
As we anticipate FDA approval, our commitment extends beyond borders. Regulatory clearances in the EU, UK, and Canada are also underway, aiming to equip healthcare providers worldwide with our cutting-edge technology.

Meet Us at AEPC 2024 in Porto: Discover firsthand how VMS+4.0 is setting new standards in cardiac imaging. We’re excited to demonstrate its capabilities and discuss its impact on the future of cardiology.

Ventripoint HeartHealth MedicalInnovation AI FDA Cardiology AEPC2024

Stay tuned for more updates or reach out to us to learn more!